ReviewInternational journal of impotence research
The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
Review in International journal of impotence research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Compound Xuanju capsules combined with phosphodiesterase-5 inhibitors as a new strategy for erectile dysfunction: a meta-analysis and trial sequential analysis.Frontiers in pharmacology · 2025Pooled it
- Pooled it
- Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension.Journal of clinical medicine · 2021Article
- Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review.International journal of retina and vitreous · 2020Review
- Multiple Pathway-Mediated Gut-Modulatory Effects ofJournal of experimental pharmacology · 2020Article
- Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.Trends in molecular medicine · 2018Review
- The effect of sildenafil on retinal blood velocity in healthy subjects.Eye and vision (London, England) · 2018Article
- Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit.Archives of medical science : AMS · 2015Article
- Drug-induced thrombosis: an update.Drug safety · 2013Review
- [Male sexuality in the elderly].Der Urologe. Ausg. A · 2012Review
- Pharmacological explanation for the medicinal use of Juniperus excelsa in hyperactive gastrointestinal and respiratory disorders.Journal of natural medicines · 2012Article
- Effect of a phosphodiesterase 5 inhibitor on pulmonary and cerebral arteries of newborn piglets with chronic hypoxia-induced pulmonary hypertension.Neonatology · 2012Article
- Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects.International neurourology journal · 2010Article
- Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique · 2010Article
- [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].Der Urologe. Ausg. A · 2009Review
- Chronic Central Serous Chorioretinopathy with Pigment Epithelium Detachment Treated with Sildenafil: A Case Report.Case reports in ophthalmologyArticle
- Anti-ischemic effects of sildenafil, vardenafil and tadalafil in heart.International journal of impotence researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphodiesterase-5 (PDE-5) inhibitors selectively inhibit PDE-5 enzymes that are present in various tissues like penile tissue, platelets, vascular, and smooth muscle tissue. The drug's actions on these tissues have lead to the successful therapeutic use in patients suffering from conditions such as erectile dysfunction (ED) and pulmonary hypertension. PDE-5 inhibitors (PDE-5i) act on the erectile tissue causing penile smooth muscle relaxation and vasodilatation leading to penile erection. In addition, in particular when used in conjunction with prostaglandin inhibitors, PDE-5i cause vasodilatation in pulmonary vasculature hence decreasing both the pulmonary arterial pressure and resistance. PDE-5i have also shown to mildly decrease blood pressure, increase cardiac index, and increase coronary blood flow in experimental animals as well as in human studies. The Food and Drug Administration (FDA) has approved three PDE-5i for the treatment of ED: sildenafil (Viagra), vardenafil (Levitra), and tadalafil (Cialis) and one for pulmonary hypertension: sildenafil (Revatio). These agents are highly selective for PDE-5 enzymes as compared to other subclasses of PDE enzymes and have the almost identical pharmacological action but slightly different pharmacokinetics. Only little data exist about long-term use of PDE-5i and their effects on different organ system. This paper reviews the current information available on chronic PDE-5 inhibitor use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.